Clinical Trial
doi: 10.1097/INF.0b013e3181be6257.
Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses
Affiliations
- PMID: 19949360
- DOI: 10.1097/INF.0b013e3181be6257
Item in Clipboard
Clinical Trial
Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses
Pediatr Infect Dis J.
2010 Mar.
Abstract
The pentavalent human-bovine reassortant rotavirus vaccine is indicated as a 3-dose series with first dose administered orally at 6 to 12 weeks with subsequent doses at 4 to 10 week intervals. In pre-licensure phase III trials, the majority followed this schedule, but there were 2956 instances where infants received a dose of pentavalent human-bovine reassortant rotavirus vaccine/placebo >10 weeks after the previous dose. Among this subset, the efficacy against any severity of disease, the reduction in utilization of healthcare resources and the safety profile after vaccination were comparable with overall results.
Similar articles
-
Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.Pediatr Infect Dis J. 2007 Dec;26(12):1099-104. doi: 10.1097/INF.0b013e31814521cb. Pediatr Infect Dis J. 2007. PMID: 18043445 Clinical Trial.
-
Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.Vaccine. 2006 May 29;24(22):4821-9. doi: 10.1016/j.vaccine.2006.03.025. Epub 2006 Mar 31. Vaccine. 2006. PMID: 16621194 Clinical Trial.
-
Prevention of rotavirus disease: guidelines for use of rotavirus vaccine.Pediatrics. 2007 Jan;119(1):171-82. doi: 10.1542/peds.2006-3134. Pediatrics. 2007. PMID: 17200286 Clinical Trial.
-
Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.Vaccine. 2009 Dec 30;27 Suppl 6:G72-81. doi: 10.1016/j.vaccine.2009.09.107. Vaccine. 2009. PMID: 20006144 Review.
-
The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.Pediatr Infect Dis J. 2006 Jul;25(7):577-83. doi: 10.1097/01.inf.0000220283.58039.b6. Pediatr Infect Dis J. 2006. PMID: 16804425 Review.
Cited by
-
Vaccines for preventing rotavirus diarrhoea: vaccines in use.Cochrane Database Syst Rev. 2019 Mar 25;3(3):CD008521. doi: 10.1002/14651858.CD008521.pub4. Cochrane Database Syst Rev. 2019. Update in: Cochrane Database Syst Rev. 2019 Oct 28;2019(10). doi: 10.1002/14651858.CD008521.pub5. PMID: 30912133 Free PMC article. Updated.
-
Updated Statement on the use of Rotavirus Vaccines: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.Can Commun Dis Rep. 2010 Jul 16;36(ACS-4):1-37. doi: 10.14745/ccdr.v36i00a04. eCollection 2010 Jul 16. Can Commun Dis Rep. 2010. PMID: 31701956 Free PMC article. No abstract available.
-
The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review.Hum Vaccin Immunother. 2021 Mar 4;17(3):880-896. doi: 10.1080/21645515.2020.1801071. Epub 2020 Sep 23. Hum Vaccin Immunother. 2021. PMID: 32966134 Free PMC article. Review.
-
Vaccines for preventing rotavirus diarrhoea: vaccines in use.Cochrane Database Syst Rev. 2019 Oct 28;2019(10):CD008521. doi: 10.1002/14651858.CD008521.pub5. Cochrane Database Syst Rev. 2019. Update in: Cochrane Database Syst Rev. 2021 Nov 17;11:CD008521. doi: 10.1002/14651858.CD008521.pub6. PMID: 31684685 Free PMC article. Updated.
-
Vaccines for preventing rotavirus diarrhoea: vaccines in use.Cochrane Database Syst Rev. 2021 Nov 17;11(11):CD008521. doi: 10.1002/14651858.CD008521.pub6. Cochrane Database Syst Rev. 2021. PMID: 34788488 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
